NeuroDerm announces the completion of enrollment and treatment in its 38-subject Phase 2 clinical trial assessing ND0612H in patients suffering from advanced Parkinson’s disease . The study is evaluating two dosing regimens of the high dose version of ND0612 compared with baseline oral standard of care.